Cardiovascular Impact of GLP-1 RAs and SGLT-2i in T2DM
European Journal of Medical Research
Summary
This study systematically reviewed and analyzed randomized controlled trials (RCTs) evaluating the cardiovascular effects of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes patients, both with and without baseline metformin use. Results indicated that these drugs reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and cardiovascular death regardless of metformin use.
Study Design
Interventions
Study Type
Outcomes
Duration and Size
Study Population
Age Range
Sex
Geography
Other Criteria
Methodology
Following PRISMA guidelines, four databases were systematically searched for RCTs assessing cardiovascular outcomes in T2DM patients using SGLT-2i or GLP-1 RAs. Data extraction focused on major adverse cardiovascular events and secondary endpoints.
Interventions
Interventions included SGLT-2 inhibitors such as dapagliflozin and empagliflozin, and GLP-1 receptor agonists like liraglutide and semaglutide, analyzed for cardiovascular outcomes.
Key Findings
Both drug classes reduced cardiovascular risks independently of baseline metformin use, with no significant interaction effects detected.
Comparison with other Studies
Comparisons with previous CVOTs confirm these drugs' cardioprotective effects regardless of metformin usage.
Journal Reference
Zhang Y, Li Z, Hao Y. Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes. Eur J Med Res. 2025;30:13. doi:10.1186/s40001-024-02241-4.